CompletedPHASE1, PHASE2NCT01648452
CNTF Implants for CNGB3 Achromatopsia
Studying Achromatopsia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Eye Institute (NEI)
- Principal Investigator
- Paul A Sieving, MD, PhDNational Eye Institute (NEI)
- Intervention
- NT-501 CNTF-releasing implant(biological)
- Enrollment
- 5 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2015
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01648452 on ClinicalTrials.govOther trials for Achromatopsia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07085533Natural History Study of Inherited Retinal DiseasesZhongmou Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02935517Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)Beacon Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02599922Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)Beacon Therapeutics
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02610582Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked AchromatopsiaSTZ eyetrial